# Ernexa Therapeutics Inc.: overview ERNA · Nasdaq · CIK 748592 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/erna.md) · [Financials](/companies/erna/financials.md) · [Filings](/companies/erna/filings.md) · [Insiders](/companies/erna/insiders.md) Latest reported revenue: [$1.0k](/filings/0001493152-26-010102.md) for Q4 FY2024, three months to 2024-12-31, from the 10-K filed Mar 13, 2026 (XBRL us-gaap:Revenues, accession 0001493152-26-010102). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [487](/filings/0001493152-25-021287.md) | [1.0 d](/filings/0001493152-26-010102.md) | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | [112.3%](/filings/0001493152-25-021287.md) | [100.0% d](/filings/0001493152-26-010102.md) | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(463.9%)](/filings/0001493152-25-021287.md) | [(269700.0%) d](/filings/0001493152-26-010102.md) | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | [(5462.8%)](/filings/0001493152-25-021287.md) | [(575900.0%) d](/filings/0001493152-26-010102.md) | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(73.70)](/filings/0001493152-25-021287.md) | not reported | [(57.76)](/filings/0001493152-26-022276.md) | [(15.19)](/filings/0001493152-26-036424.md) | [(0.15)](/filings/0001493152-25-021287.md) | not reported | [(6.95)](/filings/0001493152-26-022276.md) | [(3.40)](/filings/0001493152-26-036424.md) | | Free cash flow | $k | [(6,304) d](/filings/0001493152-25-021287.md) | [(3,545) d](/filings/0001493152-26-010102.md) | not reported | not reported | not reported | [(1,163) d](/filings/0001493152-26-010102.md) | [(2,266)](/filings/0001493152-26-022276.md) | [(4,155) d](/filings/0001493152-26-036424.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | [0.0](/filings/0001140361-24-013254.md) | [0.1](/filings/0001493152-25-010051.md) | [0.6](/filings/0001493152-26-010102.md) | not reported | | Gross margin | % | not reported | not reported | [(247.1%)](/filings/0001493152-25-010051.md) | [83.5%](/filings/0001493152-26-010102.md) | not reported | | Operating margin | % | not reported | not reported | [(31080.9%)](/filings/0001493152-25-010051.md) | [(2693.1%)](/filings/0001493152-26-010102.md) | not reported | | Net margin | % | not reported | not reported | [(31864.7%)](/filings/0001493152-25-010051.md) | [(7652.7%)](/filings/0001493152-26-010102.md) | not reported | | Diluted EPS | $ per share | [(56.61)](/filings/0001140361-23-012418.md) | [(8.06)](/filings/0001140361-24-013254.md) | [(4.08)](/filings/0001493152-25-010051.md) | [(48.96)](/filings/0001493152-26-010102.md) | [(2.24)](/filings/0001493152-26-010102.md) | | Free cash flow | $m | [(23.6)](/filings/0001140361-23-012418.md) | [(21.3)](/filings/0001140361-24-013254.md) | [(20.4)](/filings/0001493152-25-010051.md) | [(16.2)](/filings/0001493152-26-010102.md) | [(7.1)](/filings/0001493152-26-010102.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/erna/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Bleichroeder LP](/funds/1781002.md) | 2026-06-30 | $142.6k | 2,000,000 | | Unchanged | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $100.4k | 15,104 | | New +15,104 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $55.4k | 8,336 | | New +8,336 | | [Dauntless Investment Group, LLC](/funds/2044285.md) | 2026-06-30 | $39.9k | 6,000 | | New +6,000 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $37.8k | 5,684 | | New +5,684 | | [HEIGHTS CAPITAL MANAGEMENT, INC](/funds/1081698.md) | 2026-06-30 | $28.5k | 400,000 | | Unchanged | | [ARMISTICE CAPITAL, LLC](/funds/1601086.md) | 2026-06-30 | $11.4k | 160,000 | | Reduced −3,840,000 | | [Clear Street Group Inc.](/funds/1881567.md) | 2026-06-30 | $10.7k | 149,499 | | Added +199 | | [Warberg Asset Management LLC](/funds/1597506.md) | 2026-06-30 | $5.0k | 69,430 | | Reduced −184,370 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $4.1k | 57,890 | | New +57,890 | ## Recent filings [All 1,102 filings](/companies/erna/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-15 | 21:25 ET | [8-K](/filings/0001493152-26-047287.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-047287 | | 2026-09-16 | 21:30 ET | [8-K](/filings/0001493152-26-042963.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-042963 | | 2026-09-16 | 20:50 ET | [8-K](/filings/0001493152-26-042934.md) | 5.02 Departure or appointment of officers or directors | 0001493152-26-042934 | | 2026-08-06 | 21:31 ET | [10-Q](/filings/0001493152-26-036424.md) | Quarterly report, period 2026-06-30 | 0001493152-26-036424 | | 2026-07-02 | 20:40 ET | [8-K](/filings/0001493152-26-031930.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-031930 | | 2026-07-02 | 20:30 ET | [8-K](/filings/0001493152-26-031920.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001493152-26-031920 | | 2026-06-26 | 20:30 ET | [8-K](/filings/0001493152-26-030306.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001493152-26-030306 | | 2026-05-11 | 21:09 ET | [DEF 14A](/filings/0001493152-26-022281.md) | Proxy statement, period 2026-05-11 | 0001493152-26-022281 | | 2026-05-11 | 21:02 ET | [10-Q](/filings/0001493152-26-022276.md) | Quarterly report, period 2026-03-31 | 0001493152-26-022276 | | 2026-05-04 | 20:10 ET | [8-K](/filings/0001493152-26-021112.md) | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001493152-26-021112 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-010102.md), filed Mar 13, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 748592 - Tickers: ERNA, ERNAW - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:23 ET. No prices; not investment advice.